Fleury Ventures

Fleury Ventures is the corporate venture arm of Grupo Fleury, one of Brazil’s largest diagnostic medicine groups, investing into Seed and Series A startups that strengthen its diagnostic and predictive health ecosystem. The fund writes checks in the $500k to $2M range and treats healthcare AI, diagnostic software, and digital health as core thesis rather than peripheral interest. The strategic relevance is what makes this a uniquely useful partner for the right founder: Grupo Fleury operates a national network of diagnostic laboratories with massive longitudinal patient data and tight relationships with Brazilian hospitals and operadoras. For founders building AI imaging tools, diagnostic decision support, lab automation, predictive analytics, or any product that benefits from being piloted inside a high-volume diagnostic operation, Fleury Ventures is a rare strategic partner. The right founder is technical, regulatory-aware, and ready to commit to a real pilot inside Fleury’s clinical or operational pipeline rather than treating the relationship as a passive investment. Founders building consumer wellness brands, biotech assets, or care delivery models that have nothing to do with diagnostics should look elsewhere. Geographic and strategic advantage is the diagnostic data asset and the operating relationship. If your AI model needs to be validated on diverse, high-quality Brazilian data, Fleury is one of a small number of partners worldwide who can deliver that at scale. The flip side is the strategic-investor playbook: pilots have IT and regulatory cycles, exclusivity language can creep in, and the fund’s pace tracks Grupo Fleury’s broader strategy. Best entry is via the Fleury innovation team, the open-innovation programs the group runs, or a warm referral from a portfolio founder who has actually completed a Fleury pilot. Cold inbound rarely converts because the operating buy-in matters as much as the financial investment. In the pitch, lead with the diagnostic problem you solve, the operating pilot you propose, and the regulatory pathway you plan for ANVISA. Be explicit about LGPD compliance, model validation methodology, and how clinical performance is monitored in production. Caveats: negotiate exclusivity, MFN, and data-use language carefully, because subsequent strategic investors will read these provisions closely. Ask about whether the check is balance-sheet or fund-structured, what the fund’s reserves and follow-on policy look like, and how the relationship survives a leadership change at Grupo Fleury. Reference current portfolio CEOs on whether the strategic value actually materialized commercially. With those checks done, Fleury Ventures is a high-conviction partner for diagnostic and predictive AI founders building from or for Brazil.